RIKEN Program for Drug Discovery and Medical Technology Platforms

Pipeline

Pipeline
Visualizing Research and Development Progress

 The Drug Discovery and Medical Technology Platforms aim to implement innovative drug discovery and medical technologies based on areas of disease with low levels of therapeutic satisfaction, orphan drugs and new concepts. With respect to the drug creation and medical technology platforms listed in the chart below, we are currently placing maximum priority on moving to the next stage, reviewing the stages on a monthly basis to identify issues, and promoting effective research and development. For the selection of drug discovery themes, we have established guidelines to evaluate the novelty and reliability of the mechanisms, geared toward surveys of the literature and dedicated databases as well as evaluation of binding sites.


(List of themes and projects can download here.


<Projects>

Project Name Project
Leader
seg. Stage Details
S0 S1 S2 S3 L1 L2 L3 P0 P1 P2 P3
Artificial Adjuvant Vector Cells Shin-ichiro
Fujii
RM/
CT
P1     -
Cancer Treatment by NKT Cell Hiroshi
Ohno
RM/
CT
P1     -
Cancer Treatment by NKT Cell Haruhiko
Koseki
RM/
CT
P0       -
Next-Generation Implant Takashi
Tsuji
RM/
CT
P0       -
Regenerative Medicine for Retinal Degenerative Disease Michiko
Mandai
RM/
CT
P0      
Regenerative Medicine for Hair Follicle Takashi
Tsuji
RM/
CT
P0       -
Fiblodysplasia Ossificans Progressiva Kohei
Miyazono
LM P0       -
Drug for Allergic Disease Masato
Kubo
LM L3         -
Epigenetic Target III Hiroyuki
Seimiya
LM L3         -
Regenerative Medicine for Retinal Degenerative Disease Masayo Takahashi RM/
CT
        E X I T      
Regenerative Medicine for Heart Failure Akifumi Matsuyama RM/
CT
        E X I T       -
Leukemia Treatment Drug Targeting Stem Cell Fumihiko Ishikawa LM         E X I T      
Cancer Treatment by NKT Cell Masaru Taniguchi RM/
CT
        E X I T       -
Antithrombotic Drug without Hemorrhagic Side-effects Toshio Miyata LM         E X I T       -
Alzheimer Disease Hachiro Sugimoto LM         E X I T       -

*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy



<Themes>

Pink: New Theme
Cancer
Theme Name Theme Leader seg. Stage Details
S0S1S2S3L1L2L3P0P1P2P3
Epigenetic Target I Takashi
Umehara
LM L2         -
Novel DDS Carrier Motoki
Ueda
DDS L2         -
Epigenetic Target IV Hiroyuki
Aburatani
LM S3               -
Drug for Refractory Solid Cancer
Targeting Stem Cell
Kenkichi
Masutomi
LM S3               -
Artificial Adjuvant Vector Cells Shin-ichiro
Fujii
RM/
CM
S3               -
Epigenetic Target VI Akihiro
Ito
LM S2                 -
Oncogene Target Tohru
Kataoka
LM S2                 -
Epigenetic Target VII Yusuke
Furukawa
LM S2                 -
Epigenetic Target VIII Takehiko
Kamijo
LM S1                   -
Antibody Drug for NK/T Cell Lymphoma Yasuyuki
Ishii
AB         E X I T       -
Drug for Brain Tumor by Photodynamic Therapy Toshihisa Ishikawa LM         E X I T       -

*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy



Infection
Theme Name Theme Leader seg. Stage Details
S0S1S2S3L1L2L3P0P1P2P3
Antifungal Drug Minoru
Yoshida
LM L1             -
Drug for Chagas Disease Akiko
Tanaka
LM S3               -
Antibody Drug for Hepatitis B Daiki
Miki
AB S3               -
Antimalarial Drug Nobumoto
Watanabe
LM S2                 -
Drug for Hepatitis B Kenji
Ogawa
LM S1                   -
Drug for RNA viruses Kenji
Ogawa
LM S1                   -

*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy



Pink: New Theme
CNS Disease
Theme Name Theme Leader seg. Stage Details
S0S1S2S3L1L2L3P0P1P2P3
Gene therapy for
Retinitis Pigmentosa
Akishi
Onishi
GT S3               -
Alzheimer Disease Naoyuki
Taniguchi
LM S1                   -
Drug for Bipolar Disorder Tadafumi
Kato
LM S1                   -
Drug for Dementia Teijiro
Aso
LM S1                   -

*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy



Pink: New Project
Congenital Disease
Theme Name Theme Leader seg. Stage Details
S0S1S2S3L1L2L3P0P1P2P3
Drug for Hemoglobinopathy Akihiro
Ito
LM L1             -
Drug for Genetic Disorder Tadashi
Suzuki
LM S1                   -

*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy



Gastrointestinal Disease
Theme Name Theme Leader seg. Stage Details
S0S1S2S3L1L2L3P0P1P2P3
Antibody Drug for IBD Takashi
Saito
AB S3               -
Drug for IBD Mikako
Shirouzu
LM S2                 -

*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy



Pink: New Project
Basic Technology
Theme Name Theme Leader seg. Stage Details
S0S1S2S3L1L2L3P0P1P2P3
Cardiomyopathy Hidetoshi
Masumoto
BT S1                   -

*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy



Drug Discovery Support Network
Theme Name Theme Leader seg. Stage Details
Taget Valid.ScreeningLead Opt.Pre-clinicalclinical
Anticancer Drug / Antiviral Drug Kazutoshi
Mori
LM       -

*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy



<Closed Themes>

Theme Name Theme Leader seg. Stage Details
S0S1S2S3L1L2L3P0P1P2P3
Antibody Drug for cancer Targeting ErbB Shigeyuki Yokoyama AB S3               -
Antcancer Drug Targeting p53 Restriction Protein Akiko Tanaka LM S2                 -
Antiviral Drug for Influenza Yoko Aida LM S2                 -
Osteoarthritis Shiro Ikegawa AB S1                   -
Epigenetic Target Minoru Yoshida LM S1                   -
Drug for Hepatitis C Takehisa Matsumoto LM S1                   -
Drug for pulmonary Hypertension Yukihito Ishizaka LM S1                   -
New Stabilized Nucleic Acid Drug Ishiro Hirao /
Hidefumi Mukai
NA S1                   -
Alzheimer Disease Takaomi Saido LM S1                   -
Antibody Drug for Viral Liver Cirrhosis Soichi Kojima AB S3               -
Drug for HIV Yoko Aida LM S1                   -
Mucosal Vaccine Delivery System Hiroshi Ohno LM S1                   -
Antibody Drug for CD8 T-Cell Related Disease Tsuneyasu Kaisho AB S3               -
Drug for Autoimmune Disease Akari Suzuki LM S1                   -
Antibody Drug for Hepatic Disease Soichi Kojima AB S2                 -
Hay Fever Drug / Prophylaxis Drug Masaru Taniguchi V                       -
Drug for Cancer Metastasis Masatoshi Takeichi LM S1                   -
Huntington Disease Masatoshi Hagiwara LM S1                   -
Rheumatoid Arthritis Makoto Kawatani LM S3               -
Drug for Sleep Disorder Yukinari Ito LM S2                 -
PET Imaging of Apoptosis Cells Yasuko Matsumoto Diag. L1             -
Drug for AML Issay Kitabayashi AB L2           -
Epigenetic Target II Akihiro Ito LM L1             -
Epigenetic Target V Tetsu Akiyama LM S2                 -
Antibody Drug for Glioma Toru Kondo AB L2           -
Antibody Drug for Leukemia Fumihiko Ishikawa AB S3               -

*AB:Antibody, *LM:Low Molecular, *NA:Nucleic Acid, *V:Vaccin,
*RM/CT:Regenerative Medicine or Cell Therapy, *Diag.:Diagnostic
*DDS:Drug Delivery System, *BT:Basic Technology, *GT:Gene therapy


The Challenges of Rare and Incurable Diseases

 This program has embarked on research and development of rare and incurable diseases in areas where pharmaceutical companies find it difficult to engage. We are currently targeting Fibrodysplasia Ossificans Progressiva (FOP). This disease is said to afflict one in 2 million people and starts in childhood with all the muscles and surrounding membranes, tendons and ligaments in the body gradually hardening and turning to bone (heterotopic ossification). As a result, the internal structures are crushed by ossification preventing muscle stretching, walking or eating, leading to death when it becomes impossible to breathe. Patients are no longer able to move their bodies by age 30 and prolonging life until age 40 is rare. At present, the disease is considered incurable. This program expects to develop inhibitors for newly identified target proteins and we are also advancing studies of "enhanced applications" for the inhibitor to interface with pharmaceutical companies.




Promoting Alliances of Drug Discovery and Medical Technologies Themes
-Looking for Corporate Partners!-

 The program is looking for partners for the drug discovery and medical technology themes and projects mentioned above. If you are interested in any of these themes, please see the Business Development Office Page.


 

Contact